Dolomite and Clearbridge BioMedics have collaborated to develop a new instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.
Microfluidics expert, Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.
The innovative ClearCell System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood.
Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.
Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, "We are excited to be working with an innovative company like Clearbridge BioMedics.
The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science.
By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the
